Related Experiment Video
Updated: Jul 12, 2025

Assessing Retinal Microglial Phagocytic Function In Vivo Using a Flow Cytometry-based Assay
Published on: October 18, 2016
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics
Izabela Lepiarz-Raba1, Ismail Gbadamosi2, Roberta Florea3
1Laboratory for Translational Research in Neuropsychiatric Disorders (TREND), BRAINCITY: Center of Excellence for Neural Plasticity and Brain Disorders, Nencki Institute of Experimental Biology, Warsaw, Poland. i.lepiarz-raba@nencki.edu.pl.
Abstract:
Microglia, the resident immune cells of the brain, are increasingly implicated in the regulation of brain health and disease. Microglia perform multiple functions in the central nervous system, including surveillance, phagocytosis and release of a variety of soluble factors. Importantly, a majority of their functions are closely related to changes in their metabolism. This natural inter-dependency between core microglial properties and metabolism offers a unique opportunity to modulate microglial activities via nutritional or metabolic interventions. In this review, we examine the existing scientific literature to synthesize the hypothesis that microglial phagocytosis of amyloid beta (Aβ) aggregates in Alzheimer's disease (AD) can be selectively enhanced via metabolic interventions. We first review the basics of microglial metabolism and the effects of common metabolites, such as glucose, lipids, ketone bodies, glutamine, pyruvate and lactate, on microglial inflammatory and phagocytic properties. Next, we examine the evidence for dysregulation of microglial metabolism in AD. This is followed by a review of in vivo studies on metabolic manipulation of microglial functions to ascertain their therapeutic potential in AD. Finally, we discuss the effects of metabolic factors on microglial phagocytosis of healthy synapses, a pathological process that also contributes to the progression of AD. We conclude by enlisting the current challenges that need to be addressed before strategies to harness microglial phagocytosis to clear pathological protein deposits in AD and other neurodegenerative disorders can be widely adopted.
Insights
Metabolic interventions can enhance microglial phagocytosis of amyloid beta in Alzheimer's disease (AD). This review explores how modulating brain immune cell metabolism offers therapeutic potential for AD and other neurodegenerative diseases.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Metabolic Pathways
Background:
- Microglia, the brain's immune cells, play crucial roles in central nervous system health and disease.
- Microglial functions, including phagocytosis and inflammatory responses, are intrinsically linked to their metabolic state.
- Metabolic dysregulation is observed in Alzheimer's disease (AD), impacting microglial activity.
Purpose of the Study:
- To review the scientific literature on microglial metabolism and its influence on microglial functions.
- To synthesize the hypothesis that metabolic interventions can enhance microglial phagocytosis of amyloid beta (Aβ) in AD.
- To explore the therapeutic potential of modulating microglial metabolism for AD treatment.
Main Methods:
- Review of existing scientific literature on microglial metabolism and AD.
- Analysis of the effects of various metabolites (glucose, lipids, ketone bodies, etc.) on microglial properties.
- Examination of in vivo studies involving metabolic manipulation of microglial functions in AD models.
Main Results:
- Microglial functions are closely tied to their metabolic state, offering targets for intervention.
- Evidence suggests dysregulation of microglial metabolism in AD pathology.
- Metabolic manipulation studies show potential for enhancing microglial phagocytosis of Aβ.
Conclusions:
- Targeting microglial metabolism presents a promising therapeutic strategy for AD.
- Further research is needed to address challenges before clinical application for clearing pathological protein deposits.
- Understanding metabolic factors is key to harnessing microglia for neurodegenerative disease treatment.

